Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Strong 22% revenue growth and improved margins signal a promising outlook despite market headwinds.
Despite currency headwinds, Surgical Science Sweden AB (STU:4P41) reports strong operational cash flow and significant growth in educational products and EMEA revenue.
Surgical Science Sweden AB (SUSRF) reports record sales and significant growth in OEM sales, despite facing currency impacts and market challenges.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.